Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
49.81%
Operating Margin
22.99%
Net Margin
17.13%
Efficiency Metrics
Revenue per Expense Ratio
1.30
R&D as % of Revenue
8.60%
Earnings Quality
EBITDA Margin
28.18%
Income Tax Rate
20.13%
EPS
10.2300000000
Balance Sheet Analysis
Current Ratio
1.00
Cash Ratio
0.30
Working Capital
$-11.00M
Debt to Equity
9.05
Debt to Assets
49.12%
Equity Ratio
5.43%
Cash Flow Analysis
Operating Cash Flow Ratio
20.49%
Free Cash Flow Ratio
17.95%
CapEx to Revenue
2.54%
Dividends Paid
$589.00M
Stock Buybacks
$804.00M
Total Shareholder Returns
$1.39B
Cash Position Change
28.68%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 11.46%
Increased R&D investment by 10.14%
Detailed Growth Metrics
Core Performance
Revenue
9.50%
Net Income
25.39%
EPS
25.68%
Operating Income
38.11%
Operational Efficiency
R&D Expenses
10.14%
SG&A Expenses
7.66%
Operating Cash Flow
12.12%
Free Cash Flow
14.29%
Balance Sheet Health
Assets
4.07%
Debt
-0.02%
Book Value per Share
465.81%
Inventory
-21.61%
Shareholder Returns
Dividends per Share
11.46%
Shares Outstanding
-0.30%
Long Term Trends
3Y Revenue/Share
37.00%
5Y Revenue/Share
39.86%
3Y Dividend/Share
37.52%
5Y Dividend/Share
79.89%